Last updated: May 25, 2026
Sodium polystyrene sulfonate (SPS) is supplied by multiple manufacturers across the US, EU, and other regions, but supplier lists vary by strength (powder vs. suspension), form (calcium/sodium salt variants), and regulatory status in each market. For procurement planning, the actionable path is to anchor sourcing to (1) the drug product’s approved labeling in each geography, (2) the Orange Book listing (US) for the specific active ingredient and dosage form, and (3) the contract terms around whether the supplier can ship during supply disruptions, including any known shortages.
What is sodium polystyrene sulfonate supplied as (and why it changes the supplier list)?
SPS is an ion-exchange resin used to reduce potassium levels in hyperkalemia by binding potassium in the gut. Supply availability depends on whether a buyer needs:
- Drug product form: powder for oral suspension vs. ready-to-use suspension (where available).
- Salt form: SPS is the sodium form; some markets carry calcium polystyrene sulfonate (CPS) as an alternative resin.
- Regulatory listing: the same molecule may have different brand names, strengths, and product presentations by country.
Procurement implication: in tenders, specification wording should name the approved drug product (brand/generic plus dosage form) and not only “sodium polystyrene sulfonate,” because alternate resin salts and different presentations may be substituted.
Who supplies sodium polystyrene sulfonate in the US?
In the US, SPS product supply and procurement typically track the FDA Orange Book listings for the relevant dosage form. The Orange Book is the primary way to confirm which products are approved as SPS and are therefore eligible for US distribution under that name.
Data needed to list suppliers accurately: a complete supplier enumeration must be tied to specific Orange Book product entries (manufacturer/labeler, dosage form, NDA/ANDA). Without the actual Orange Book pull (NDA numbers and labeler/manufacturer fields) for SPS products, a “supplier list” risks mixing in resin alternatives or non-US distribution channels.
Which companies manufacture sodium polystyrene sulfonate internationally?
International SPS sourcing is commonly split across:
- Brand originators and branded-market manufacturers that hold local marketing authorizations.
- Generic API and finished-dose producers that supply local distributors and wholesalers.
- Specialty distributors that control procurement channels during shortages.
Procurement implication: for global sourcing, buyers usually need to qualify each supplier by:
- finished-dose regulatory authorization in the buyer’s destination market,
- GMP manufacturing site approvals,
- batch release controls and COA traceability, and
- historical fill rates during shortages.
How do calcium polystyrene sulfonate (CPS) alternatives affect SPS supplier strategy?
Where SPS becomes constrained, some systems shift to CPS in protocols and formularies. That can change sourcing demand because tenderers may accept an alternative resin salt if the contract allows substitution.
Contracting implication: if the buyer requires “SPS only,” substitution clauses should exclude CPS. If substitution is permitted, procurement should maintain parallel supplier qualification for CPS to preserve continuity.
What to check in supplier qualification for SPS?
High-risk supplier issues tend to be operational rather than chemical, since SPS drug substances are well-defined. Qualification should emphasize:
- Regulatory status in your market: finished drug product authorization and labeling match.
- Dosage form match: powder vs suspension; any excipient differences that affect dispensing.
- Supply continuity: history of allocation, backorders, and lead times.
- Quality systems: deviation history, CAPA responsiveness, and batch-to-batch consistency.
- Packaging and shelf life: alignment with your storage and dispensing workflow.
What generic entry risks or shortages affect sodium polystyrene sulfonate supply?
SPS is a mature, older drug, but the supply risk is mostly tied to:
- capacity allocation and resin manufacturing economics,
- finished-dose manufacturing continuity,
- and distribution constraints during periods of high demand (e.g., hyperkalemia treatment spikes).
Procurement implication: building multiple qualified suppliers and maintaining safety stock are more impactful than relying on a single-source tender model.
How does Orange Book status determine which suppliers are real for US procurement?
For the US, the “who can supply” question is answered by the Orange Book entries for each SPS dosage form. The Orange Book gives:
- NDA/ANDA identifiers
- Applicant/holder
- active ingredient and dosage form
- patent listings (where applicable)
Actionable procurement step: tie supplier bids to the exact Orange Book-listed product so the tender does not accept a non-equivalent SPS presentation.
Key Takeaways
- SPS supplier availability depends on the specific finished-dose product form and the salt and formulation presentation required by the buyer.
- In the US, the definitive supplier list must be built from FDA Orange Book SPS product entries for the buyer’s exact dosage form.
- Tender specifications should state finished drug product and dosage form to prevent inadvertent substitution with other resin salts or presentations.
- Supplier qualification should focus on regulatory authorization, GMP site performance, supply continuity, and batch traceability.
FAQs
- Can hospitals substitute sodium polystyrene sulfonate with calcium polystyrene sulfonate without a procurement breach?
- What dosage forms of sodium polystyrene sulfonate are typically contracted for inpatient use?
- How should buyers structure SPS tenders to ensure dosage-form equivalence?
- What documentation should be required from SPS suppliers during shortages?
- How do Orange Book listings affect SPS contracting for US distribution?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Orange Book database).
